Does RSV vaccination in pregnancy keep babies out of the hospital?

Short answer: yes, it appears to help, and the new evidence is encouraging.

A June 2026 study in JAMA Network Open found that babies whose mothers received the RSV vaccine during pregnancy were less likely to be hospitalized with RSV in the first 90 days of life. That matters because the youngest babies face the highest risk of severe RSV illness. But this was a real-world observational study, not a randomized trial, so it strengthens the evidence without answering every question.

What the new study found

The study looked at 274 infants 90 days old or younger who were hospitalized with acute respiratory illness in one western Pennsylvania health system during the 2023 to 2024 and 2024 to 2025 RSV seasons. Researchers used a test-negative case-control design, comparing babies who tested positive for RSV with similar hospitalized babies who tested negative.

In plain language, the main finding was this: maternal RSV vaccination was associated with about a 68% lower chance of RSV-related hospitalization in the first 90 days of life. The estimate for RSV-related lower respiratory tract disease hospitalization was about 69%. Among babies in the first month of life, the estimate was even higher, at roughly 74%.

That does not mean the vaccine guarantees a baby will avoid RSV or hospitalization. It means that, in this study, RSV hospitalization was meaningfully less common among infants whose mothers had been vaccinated during the recommended pregnancy window.

Why this matters

This is the kind of evidence many families and clinicians have been waiting for: not just trial data, but U.S. real-world results after the vaccine moved into routine care. The new paper supports the basic idea behind maternal vaccination late in pregnancy: antibodies made by the pregnant person cross the placenta and help protect the baby during the first months after birth, when RSV can be most dangerous.

It is also worth noting what this study does not do. It does not replace earlier trial evidence, and it does not by itself settle every comparison with infant antibody protection in every situation. It mainly strengthens confidence that the current maternal-vaccine approach is working in practice.

What CDC and ACOG currently recommend

CDC recommends a single dose of Abrysvo during weeks 32 through 36 of pregnancy, given seasonally from September through January in most of the United States. ACOG gives the same basic counseling message for eligible pregnant patients.

Timing matters. CDC says the vaccine should be given at 32 weeks 0 days through 36 weeks 6 days of pregnancy. If someone is already past 36 weeks 6 days, CDC says vaccination is not recommended because there may not be enough time for protective antibodies to develop and cross the placenta before birth. In that situation, the baby should receive RSV antibody protection instead.

There is another practical point many families miss: Abrysvo is the only RSV vaccine recommended for pregnancy. Other RSV products used in adults are not approved for pregnancy.

CDC also says that if someone already received a maternal RSV vaccine in a previous pregnancy, another dose is not currently recommended in a later pregnancy. Instead, the next baby should receive infant RSV antibody protection after birth.

If the maternal vaccine was missed, what happens next?

Missing the pregnancy vaccine window does not mean a baby is unprotected. CDC recommends infant RSV antibody protection for babies younger than 8 months whose mothers did not get the maternal RSV vaccine during pregnancy.

ACOG also notes that even when a mother was vaccinated, a pediatric clinician may still recommend infant antibody protection in some situations, such as birth occurring less than 14 days after vaccination, certain high-risk infant conditions, or concerns that enough antibodies may not have transferred before birth.

So the practical question is often not vaccine or nothing. It is which strategy best fits the timing of pregnancy, due date, RSV season, and the baby’s risk level.

Maternal vaccine vs infant antibody: how they differ

CDC describes both approaches as ways to protect babies from severe RSV, and says most babies do not need both.

The maternal vaccine works indirectly. The pregnant person gets vaccinated, develops antibodies over about two weeks, and passes that protection to the baby before birth. CDC says that protection lasts about 6 months after birth.

Infant antibody protection works directly. The baby receives ready-made antibodies, which provide immediate protection. CDC says that protection lasts at least 5 months.

In everyday terms, maternal vaccination may be the simpler option when the pregnancy lines up with the recommended fall and winter timing. Infant antibody protection becomes especially important when the pregnancy vaccine window was missed, birth happened too soon after vaccination, or the baby has factors that raise concern about severe RSV.

How strong is this new evidence?

Strong enough to be useful, but not strong enough to treat as the final word.

The study has real advantages. It used actual U.S. hospital data, focused on a clinically important outcome, and looked at the exact period when babies are most vulnerable. The size of the effect was also broadly consistent with earlier clinical-trial results.

But there are limitations. The study came from a single health system in western Pennsylvania. It was observational, which means the vaccinated and unvaccinated groups may have differed in ways the researchers could not fully measure. And the number of vaccinated babies who still became RSV cases was small, which makes the estimates less precise.

That is why the best reading of the paper is careful optimism: the benefit looks real, but more data from larger and more diverse settings are still needed, especially to understand durability of protection and how well the strategy performs across different populations and seasons.

What about safety?

CDC and FDA continue to monitor RSV vaccine safety. CDC says common side effects after maternal vaccination are usually mild and can include headache, nausea, and pain at the injection site. CDC also notes that hypertensive disorders of pregnancy, including preeclampsia, remain an area under further study.

CDC says adverse events can be reported to VAERS. That does not mean there is proof of a serious problem. It means the vaccine is being watched the way newer vaccines and preventive products usually are.

Will insurance cover it?

Coverage can vary, so it is worth checking before an appointment. CDC says many private plans cover the maternal RSV vaccine and infant RSV antibody products, though out-of-pocket costs can still depend on the plan and where the service is billed. CDC also says Medicaid and CHIP generally must cover ACIP-recommended vaccines without cost-sharing, and the Vaccines for Children program can cover eligible children for certain infant RSV products.

In real life, access can still depend on what a clinic, hospital, or pharmacy has in stock, and on whether the birth happens during RSV season. That is one reason families may want to ask about the plan before delivery, not after.

What readers can do

If you are pregnant and expect to be 32 to 36 weeks along during September through January, ask your obstetric clinician which RSV prevention plan makes the most sense for your baby. Useful questions include:

Will I still be in the recommended vaccine window before delivery?
If I miss that window, what is the plan for infant antibody protection?
If I was vaccinated in a prior pregnancy, what should this baby receive?
Will my insurance cover the vaccine or infant antibody, and where can I get it?

If you already have a newborn, ask the baby’s clinician whether your infant is considered protected through maternal vaccination or should receive an RSV antibody instead.

And regardless of prevention strategy, seek prompt medical care if a young baby has trouble breathing, pauses in breathing, worsening feeding, signs of dehydration, unusual sleepiness, or a bluish color around the lips. Those symptoms need urgent attention.

The bottom line

Yes, the new study suggests the RSV vaccine in pregnancy really does help keep some babies out of the hospital, especially in the first three months of life. But it is one important piece of evidence, not the whole decision.

The current practical takeaway is the same one CDC and ACOG have been giving: for most eligible pregnancies, maternal vaccination is a reasonable way to protect a baby from severe RSV. If that window is missed, infant antibody protection offers another path. The best choice depends on timing, medical context, and what is available where you live.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.